AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26638911
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of resveratrol plus 10 mg of piperine
Trial: 22045316
Drug: DHEA (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (130 mg)
Trial: 10094425
Drug: Standard monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monotherapy (Carbamazepine or Phenytoin)
Trial: 2347116
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol beer (reduced weekly alcohol intake from 481 +/- 47 mL to 52 +/- 5 mL)
Trial: 31980448
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of azathioprine (AZA) to second anti-TNF therapy
Trial: 31980448
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with second anti-TNF (no AZA)
Trial: 30431709
Drug: Bioabsorbable steroid-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-releasing implants (mometasone furoate, 370 μg)
Trial: 30431709
Drug: Control (contralateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (contralateral side without implant)
Trial: 30026614
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy for Cancer-related Insomnia (BBT-CI)
Trial: 20617484
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CG, n=8)
Trial: 17975981
Drug: Vinblastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (2 mg/m2, IV, q 1 wk)
Trial: 12425728
Drug: Phytosterol-enriched chocolate
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol-enriched chocolate (1.8 g unesterified phytosterols/d)
Trial: 7540058
Drug: High-dose magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose magnesium regimen (4.2 +/- 0.7 g magnesium sulfate before bypass, followed by 11.9 +/- 2.8 g magnesium chloride until the first postoperative morning, and 5.5 +/- 1.0 g until the second postoperative morning)
Trial: 7540058
Drug: Low-dose magnesium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose magnesium regimen (2.9 +/- 0.5 g magnesium sulfate at the first postoperative morning, and 1.4 +/- 0.1 g at the second postoperative morning)
Trial: 29920521
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLL) applied at auriculotherapy points
Trial: 29920521
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of LLL treatment (control group)
Trial: 27431736
Drug: IB1 topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IB1 topical protective lotion
Trial: 28817997
Drug: Cladribine 5.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 5.25 mg/kg
Trial: 22017519
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (both doses)
Trial: 17261234
Drug: Antibiotic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapies based on stratification by disease severity
Trial: 17261234
Drug: Antibiotic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapies utilized in the trial (specific antibiotics not mentioned)
Trial: 11255901
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription (92 patients)
Trial: 11255901
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription (99 patients)
Trial: 9734940
Drug: 30 IU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 IU/m2 somatropin per week as daily subcutaneous injections
Trial: 9734940
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-consent group)
Trial: 28926855
Drug: Once-daily Fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Fluticasone Furoate/Vilanterole (FF/VI) 200/25 µg via ElliptaTM DPI
Trial: 28926855
Drug: Twice-daily Fluticasone
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily Fluticasone Propionate/Salmeterol (FP/SAL) 500/50 µg via DiskusTM DPI
Trial: 12871541
Drug: Antidote administration
RxNorm normalized name: thiosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidote administration (specific antidotes)
Trial: 12871541
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K administration
Trial: 10692930
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (2 drops of 0.3% ophthalmic solution every 30 min for 3 h, then every 60 min for the next 3 h)
Trial: 10692930
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (single dose of 1000 mg 6 h before surgery)
Trial: 8836872
Drug: Beta-carotene (31.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (31.4 mg/day) plus D-alpha-tocopherol acetate (720 IU/day) supplements
Trial: 8354735
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in maintenance therapy)
Trial: 26909786
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) + Total Intravenous Anesthesia (TIVA)
Trial: 21055963
Drug: Standard COP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard COP group (0.5 g/kg albumin in priming, COP target at 15 mmHg)
Trial: 16567158
Drug: TV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV group (children who watched more daily hours of TV)
Trial: 12627041
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day for 21 days)
Trial: 10689253
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of contrast (1.3 mL in 50 mL normal saline initially at 4.0 mL/min)
Trial: 10689253
Drug: Bolus injections
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injections of contrast (10 microL/kg each over a period of 30 to 60 seconds)
Trial: 7503004
Drug: Oral propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone 600 mg
Trial: 2032708
Drug: Miconazole therapy
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole therapy
Trial: 2032708
Drug: Oral nystan
RxNorm normalized name: nystatin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nystan
Trial: 2032708
Drug: Oral yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral yeast carriage rate in women
Trial: 30427246
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (BRJ) 140 mL daily (∼800 mg/d nitrate)
Trial: 23466709
Drug: S boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S boulardii (1 g/day)
Trial: 11376827
Drug: enalapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (10-20 mg per day)
Trial: 11376827
Drug: losartan (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (50-100 mg per day)
Trial: 9401542
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment at a dose of 0.1 IU/kg/day for 2 years (group A)
Trial: 9401542
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment at a dose of 0.2 IU/kg/day for the second year (group B)
Trial: 28325123
Drug: 5% menthol
RxNorm normalized name: MENTHOL 5 g TOPICAL PATCH [Cold Hot Medicated Patch 5% Menthol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% menthol gel applied to the skin over the quadriceps muscle
Trial: 16575035
Drug: Betamethasone 8
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 8 mg iv
Trial: 16575035
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 mL (placebo)
Trial: 1525903
Drug: Anxiolytics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytics and Mg-lactate
Trial: 3897612
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of S6472 given orally before a meal
Trial: 3897612
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of S6472 given orally after a light meal
Trial: 3897612
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of S6472 given orally after a usual meal
Trial: 3897612
Drug: 750 to
RxNorm normalized name: benzalkonium chloride 1:750 TOPICAL TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 to 1,500 mg/day of S6472
Trial: 26655188
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pharmacological agents)
Trial: 10456621
Drug: Low fixed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fixed dose of warfarin (1.25 mg/day) for an additional month (group B)
Trial: 2404052
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose simvastatin
Trial: 2404052
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose simvastatin
Trial: 10404843
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 to 40 mg)
Trial: 856370
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire on chest pain and intermittent claudication
Trial: 31007215
Drug: Topical Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tacrolimus 0.03% ointment
Trial: 31007215
Drug: Topical Dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Dexamethasone 0.05% ointment
Trial: 23559402
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral dose of olanzapine
Trial: 19220279
Drug: Cetilistat 50
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 50 mg t.i.d. (n = 7)
Trial: 19220279
Drug: Cetilistat 60
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 60 mg t.i.d. (n = 9)
Trial: 19220279
Drug: Cetilistat 100
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 100 mg t.i.d. (n = 7)
Trial: 19220279
Drug: Cetilistat 120
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 120 mg t.i.d. (n = 9)
Trial: 19220279
Drug: Cetilistat 150
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 150 mg t.i.d. (n = 16)
Trial: 19220279
Drug: Cetilistat 240
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 240 mg t.i.d. (n = 9)
Trial: 19220279
Drug: Cetilistat 300
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 300 mg t.i.d. (n = 9)
Trial: 19220279
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg t.i.d. (n = 9)
Trial: 11561263
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.25% plus fentanyl 2.5 microg/mL (group BF)
Trial: 11561263
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.25% (group B)
Trial: 11561263
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.125% plus fentanyl 2.5 microg/mL (group DBF)
Trial: 29703289
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (ocular bandage gel 4 times a day for 14 days and bandage contact lens)
Trial: 29703289
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (ocular bandage gel 4 times a day for 14 days)
Trial: 16076697
Drug: Sequential, dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential, dose-dense epirubicin plus docetaxel
Trial: 11920355
Drug: 7.5% icodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% icodextrin solution (Extraneal)
Trial: 8529496
Drug: Chromium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium supplementation (220 micrograms elemental chromium daily for 90 days)
Trial: 1760827
Drug: verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 120 sustained-release
Trial: 1760827
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy (ISDN + verapamil)
Trial: 7161777
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5 to 25 mg oral or intramuscular
Trial: 29565948
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg SR-nitrite, BID
Trial: 29565948
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg SR-nitrite, BID
Trial: 12595814
Drug: Selective phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective phosphodiesterase type-5 inhibitors
Trial: 10893703
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine 0.3 mg/kg
Trial: 10893703
Drug: (R)-ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-ketamine 0.5 mg/kg
Trial: 10893703
Drug: (S)-ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-ketamine 0.15 mg/kg
Trial: 1486186
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily in the morning
Trial: 6489418
Drug: 22 registered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 registered pharmaceutical specialities
Trial: 17663104
Drug: Routine obstetric
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine obstetric treatment with catgut embedding at Zusanli (ST 36) and Shangjuxu (ST 37)
Trial: 17663104
Drug: Routine obstetric
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine obstetric treatment
Trial: 12017421
Drug: Pramlintide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (all doses)
Trial: 9890379
Drug: IV Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Ondansetron (4 mg)
Trial: 1646490
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (CY 216)
Trial: 1646490
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous unfractionated heparin
Trial: 6752926
Drug: Antrafenine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antrafenine (up to 1200 mg daily)
Trial: 6752926
Drug: Paracetamol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (up to 4 g daily)
Trial: 29130845
Drug: Restrictive red-cell
RxNorm normalized name: Bos taurus red blood cell preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive red-cell transfusion strategy (transfuse if hemoglobin <7.5 g/dL)
Trial: 29130845
Drug: Liberal red-cell
RxNorm normalized name: Bos taurus red blood cell preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal red-cell transfusion strategy (transfuse if hemoglobin <9.5 g/dL in operating room or ICU, <8.5 g/dL in non-ICU ward)
Trial: 23975474
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC) using the Dáder method
Trial: 17513805
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Trial: 17513805
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Trial: 17513805
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of ED+G
Trial: 17513805
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of ED+G
Trial: 15208047
Drug: Lower-dose formulation
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose formulation of Depo-Provera (104 mg/0.65 mL)
Trial: 15208047
Drug: Original formulation
RxNorm normalized name: Zegerid (Original Formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original formulation of Depo-Provera (150 mg/mL)
Trial: 26538423
Drug: High-dose hemithoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hemithoracic radiotherapy
Trial: 26538423
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and extrapleural pneumonectomy
Trial: 23744726
Drug: Exenatide plus
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide plus metformin
Trial: 21295742
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones 120 mg/d
Trial: 21295742
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones 80 mg/d
Trial: 21295742
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (both doses)
Trial: 7588455
Drug: Concomitant b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant b.i.d. medications
Trial: 7588455
Drug: Thrice-daily (t.i.d.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily (t.i.d.) medications
Trial: 7588455
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily (q.i.d.) medications
Trial: 27500463
Drug: Sativex® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex® treatment
Trial: 26158157
Drug: Pyridoxine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (60 mg/d)
Trial: 23020850
Drug: Belly dance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belly dance (16 weeks, twice a week)
Trial: 19053980
Drug: 3.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g/d prebiotic
Trial: 19053980
Drug: 7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/d prebiotic
Trial: 19053980
Drug: 7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/d placebo
Trial: 15068719
Drug: Continuous veno-venous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous veno-venous hemofiltration (CVVH) combined with conventional therapy
Trial: 9850013
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg transbuccal melatonin
Trial: 2531117
Drug: Single-dose spectinomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spectinomycin (TRO: 2 g intramuscularly)
Trial: 2531117
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (APPG: 4.8 x 10(6) units) plus 1 g of probenecid
Trial: 2531117
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (APPG)